 BURLINGTON, Mass., April 28, 2021 GLOBE NEWSWIRE -- Flexion Therapeutics, Inc. Nasdaq:FLXN will present preliminary data from a Phase 1 single ascending dose SAD trial of FX201 at the 2021 American Society of Gene Cell Therapy ASGCT annual meeting taking place virtually May 11-14, 2021. 